What type of targeted biological agents does bimekizumab belong to?

Bimekizumab is a new type of targeted biological agent. Its main mechanism of action is to inhibit the activity of two cytokines, IL-17A and IL-17F. IL-17A and IL-17F are key immune regulatory molecules in inflammatory diseases and participate in a variety of immune responses, especially in diseases related to immunity and inflammation, such as plaque psoriasis, psoriatic arthritis, etc. Bicizumab simultaneously inhibits these two cytokines through a dual mechanism of action, providing a more comprehensive and precise anti-inflammatory treatment.

IL-17A is a cytokine produced by T cells and is widely involved in the occurrence of a variety of immune-mediated diseases. In immune skin diseases such as psoriasis, IL-17A exacerbates skin damage and pathological processes by activating inflammatory responses and recruiting immune cells. IL-17F and IL-17A are highly similar in function and also play an important role in immune responses. By blocking the activity of these two cytokines simultaneously, bichizumab can effectively reduce the inflammatory response and alleviate the pathological conditions caused by IL-17A and IL-17F, especially in psoriasis and other immune-mediated diseases.

As a humanized monoclonalIgG1 antibody, bicizumab can highly selectively target and inhibit IL-17A and IL-17F, reducing their overactivation of the immune system. This dual mechanism of action gives it a unique advantage among targeted biological agents, enabling precise intervention in immune inflammation, reducing pathological damage and improving patients' clinical symptoms.

Due to its unique mechanism of action, bicizumab is regarded as an innovative biological agent and has achieved significant efficacy in the treatment of some immune-related diseases. It is mainly used to treat diseases such as psoriasis and ankylosing spondylitis, and is expected to find applications in more immune diseases.

Reference materials:https://www.drugs.com/bimekizumab.html